Cell therapies for acute and chronic traumatic brain injury

9Citations
Citations of this article
6Readers
Mendeley users who have this article in their library.
Get full text

Abstract

Traumatic brain injury (TBI) is a global health problem, for which there are no approved therapies. Advances in acute clinical care have improved post-TBI survival, yet many patients are left with chronic TBI-related disabilities (i.e. chronic TBI). Existing treatments that focus on rehabilitation and symptom management do not modify the disease and have limited effectiveness. Consequently, chronic TBI-related disabilities remain a significant unmet medical need. Cell therapies have neuroprotective and neurorestorative effects which are believed to modify the disease. In this article, we review the safety and efficacy of cell therapies in early-phase clinical studies that have shown potential to improve outcomes in acute to chronic phases of TBI.

Cite

CITATION STYLE

APA

Kawabori, M., Chida, D., Nejadnik, B., Stonehouse, A. H., & Okonkwo, D. O. (2022). Cell therapies for acute and chronic traumatic brain injury. Current Medical Research and Opinion. Taylor and Francis Ltd. https://doi.org/10.1080/03007995.2022.2141482

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free